Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Abstract 3427: Gatekeeper inactivation drives glioma progression into secondary glioblastoma

View through CrossRef
Abstract <Glioblastoma (GBM) is the most common and lethal form of brain cancer in humans. Median survival is 15 months with best available treatment. Most GBMs arise de novo (primary GBM), but 5 - 10% progress from lower grade gliomas (secondary GBM). As progression of low grade glioma into secondary GBM significantly impacts prognosis, a better understanding of this process is paramount for treatment and monitoring of affected patients. In this study, we applied whole genome and transcriptome sequencing to primary glioma and relapsed secondary GBM tissue from seven patients with progression. All primary gliomas carried IDH1 mutations, and in all cases the mutation was inherited by the secondary GBM. ATRX alterations in all five astrocytomas and TERT promoter mutations in both 1p19q-codeleted oligoastrocytomas were also inherited in progressed tumors. In five patients, progression was associated with increased genomic instability, whereas mutation load was significantly increased in two other patients. One of them exhibited a hypermutation signature caused by a mutation in the proofreading domain of DNA polymerase epsilon, while the second had lost both copies of the DNA mismatch protein MSH2. In addition, both 1p19q-codeleted tumors had acquired focal inactivating deletions of the protein tyrosine phosphatase PTPRD at progression, suggesting a novel driver mechanism for GBM progression. The most common progression-related genomic alterations were CDKN2A deletions, TP53 mutations, RB1 deletions, PTEN deletions, and deletions of genes crucial to the double strand break repair pathway. Taken together, progression into secondary GBM was significantly related to deletions in tumor suppressor genes as well as TP53 mutations. Disruption of these gatekeepers appears to be a significant mechanism for glioma progression.> Citation Format: Kirsi Johanna Granberg, Matti Annala, Serafiina Jaatinen, Joonas Haapasalo, Olli Yli-Harja, Hannu Haapasalo, Wei Zhang, Matti Nykter. Gatekeeper inactivation drives glioma progression into secondary glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3427.
Title: Abstract 3427: Gatekeeper inactivation drives glioma progression into secondary glioblastoma
Description:
Abstract <Glioblastoma (GBM) is the most common and lethal form of brain cancer in humans.
Median survival is 15 months with best available treatment.
Most GBMs arise de novo (primary GBM), but 5 - 10% progress from lower grade gliomas (secondary GBM).
As progression of low grade glioma into secondary GBM significantly impacts prognosis, a better understanding of this process is paramount for treatment and monitoring of affected patients.
In this study, we applied whole genome and transcriptome sequencing to primary glioma and relapsed secondary GBM tissue from seven patients with progression.
All primary gliomas carried IDH1 mutations, and in all cases the mutation was inherited by the secondary GBM.
ATRX alterations in all five astrocytomas and TERT promoter mutations in both 1p19q-codeleted oligoastrocytomas were also inherited in progressed tumors.
In five patients, progression was associated with increased genomic instability, whereas mutation load was significantly increased in two other patients.
One of them exhibited a hypermutation signature caused by a mutation in the proofreading domain of DNA polymerase epsilon, while the second had lost both copies of the DNA mismatch protein MSH2.
In addition, both 1p19q-codeleted tumors had acquired focal inactivating deletions of the protein tyrosine phosphatase PTPRD at progression, suggesting a novel driver mechanism for GBM progression.
The most common progression-related genomic alterations were CDKN2A deletions, TP53 mutations, RB1 deletions, PTEN deletions, and deletions of genes crucial to the double strand break repair pathway.
Taken together, progression into secondary GBM was significantly related to deletions in tumor suppressor genes as well as TP53 mutations.
Disruption of these gatekeepers appears to be a significant mechanism for glioma progression.
> Citation Format: Kirsi Johanna Granberg, Matti Annala, Serafiina Jaatinen, Joonas Haapasalo, Olli Yli-Harja, Hannu Haapasalo, Wei Zhang, Matti Nykter.
Gatekeeper inactivation drives glioma progression into secondary glioblastoma [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL.
Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3427.

Related Results

Investigating the role of the apelinergic system in glioblastoma
Investigating the role of the apelinergic system in glioblastoma
<p>Elucidating the molecular signalling circuitry that underpins the pathogenesis of cancers is critical to understanding and developing effective treatment paradigms for can...
Understanding glioblastoma : cell identity in tissue space
Understanding glioblastoma : cell identity in tissue space
<p dir="ltr"><b>Abstract</b></p><p dir="ltr">Glioblastoma is the most prevalent form of brain cancer among adults. Inherently malignant and aggressive...
Understanding glioblastoma : cell identity in tissue space
Understanding glioblastoma : cell identity in tissue space
<p dir="ltr"><b>Abstract</b></p><p dir="ltr">Glioblastoma is the most prevalent form of brain cancer among adults. Inherently malignant and aggressive...
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma
PAMs inhibits monoamine oxidase a activity and reduces glioma tumor growth, a potential adjuvant treatment for glioma
Abstract Background Monoamine oxidase (MAO) A catalyzes oxidative deamination of monoamine neurotransmitters and dietary amines and regulates brain development and functions. Recen...
PLEKHA4 is a prognostic biomarker and correlated with immune infiltrates in glioma
PLEKHA4 is a prognostic biomarker and correlated with immune infiltrates in glioma
Abstract Background Gliomas are the most common and life-threatening intracranial tumors. Immune-infiltration of the tumor microenvironment significantly affects tumor pro...
Effect of glycolysis inhibition by miR-448 on glioma radiosensitivity
Effect of glycolysis inhibition by miR-448 on glioma radiosensitivity
OBJECTIVEAlthough glucose metabolism reengineering is a typical feature of various tumors, including glioma, key regulators of glycolytic reprogramming are still poorly understood....
The expression of DLGAP5 associate with progression and prognosis in glioma
The expression of DLGAP5 associate with progression and prognosis in glioma
Glioma is the most common primary malignant tumor of the central nervous system and is related to poor clinical outcomes. At present, the standard treatment of glioma in clinical p...

Back to Top